Comparative Pharmacology
Head-to-head clinical analysis: TWIRLA versus TYDEMY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TWIRLA versus TYDEMY.
TWIRLA vs TYDEMY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive that inhibits gonadotropin secretion (FSH and LH) through estrogen and progestin, suppressing ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
Tydemy is a combination of drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropins, inhibiting ovulation and altering cervical mucus and endometrium. Ethinyl estradiol provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
One patch applied to the lower abdomen, buttocks, or upper torso once weekly for 3 consecutive weeks (21 days) followed by a 7-day patch-free interval. Each patch releases 120 mcg of levonorgestrel and 30 mcg of ethinyl estradiol per 24 hours.
50 mg orally once daily.
None Documented
None Documented
Levonorgestrel: approximately 25 hours (range 17-30 h). Ethinyl estradiol: approximately 13 hours (range 10-16 h). Clinical context: Steady state reached within 5-7 days; half-life supports once-weekly dosing.
Terminal elimination half-life is 6–8 hours in adults with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life may extend to 20–30 hours.
Primarily renal (about 60% as metabolites, <10% unchanged) and fecal (about 30-40% as metabolites).
Primarily renal excretion: approximately 80% of the dose is recovered in urine as unchanged drug. Biliary/fecal elimination accounts for <15%.
Category C
Category C
Hormonal contraceptive
Hormonal contraceptive